AMISHI YOGESHSHAHAMISHI YOGESH SHAH12370SHAH, AMISHI YOGESHAssistant Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonGenitourinary Medical OncologyMD AndersonCHRISTOPHER GWOODCHRISTOPHER G WOOD8666WOOD, CHRISTOPHER GProfessorARLENE ODELIASIEFKER-RADTKEARLENE ODELIA SIEFKER-RADTKE8840SIEFKER-RADTKE, ARLENE ODELIAAssociate ProfessorERICJONASCHERIC JONASCH9049JONASCH, ERICProfessorJIANJUNGAOJIANJUN GAO9668GAO, JIANJUNAssistant ProfessorNIZAR MTANNIRNIZAR M TANNIR8865TANNIR, NIZAR MProfessorSURENAMATINSURENA MATIN9030MATIN, SURENAProfessorJOSE ANTONIOKARAMJOSE ANTONIO KARAM9608KARAM, JOSE ANTONIOAssociate Professor74Professor10Assistant Professor14Associate Professor1155 Pressler StHouston77030-3721TX1.896520.0143357133research areas4.80210.0497807112coauthor of109.8367.7279360similar to1159selected publicationsAuthorship 866303Authorship 866676Urology Case ReportsClinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinib. Urology Case Reports. 3:18-20.Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mrcc) treated with sunitinibBJU InternationalManagement and outcomes of patients with renal medullary carcinoma. BJU International. Management and outcomes of patients with renal medullary carcinomaD007167Procedures83233380.374551ImmunotherapyD014565Disorders861080.905938Urogenital NeoplasmsD002292Disorders43623170.406865Carcinoma, Renal CellD007680Disorders57230120.367869Kidney NeoplasmsD011581Procedures881310.918744Psychological Tests26120560Shah AY, Karam JA, Lim ZD, Ng CS, Tannir NMUrology case reportsClinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy? Urol Case Rep. 2015 Mar 01; 3(2):18-20.Urol Case Rep2015-03-01T00:00:002015Clinical and pathological complete remission in a patient with metastatic renal cell carcinoma (mRCC) treated with sunitinib: Is mRCC curable with targeted therapy?27860149Shah AY, Karam JA, Malouf GG, Rao P, Lim ZD, Jonasch E, Xiao L, Gao J, Vaishampayan UN, Heng DY, Plimack ER, Guancial EA, Fung C, Lowas SR, Tamboli P, Sircar K, Matin SF, Kimryn Rathmell W, Wood CG, Tannir NMBJU internationalManagement and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU Int. 2017 12; 120(6):782-792.BJU Int2016-12-09T00:00:002016Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.28591094Malouf GG, Joseph RW, Shah AY, Tannir NMClinical advances in hematology & oncology : H&ONon-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities. Clin Adv Hematol Oncol. 2017 May; 15(5):409-418.Clin Adv Hematol Oncol2017-05-01T00:00:002017Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities.28579283Campbell MT, Shah AY, Matin SF, Siefker-Radtke AOUrologic oncologyOptimizing management of upper tract urothelial carcinoma. Urol Oncol. 2017 07; 35(7):492-498.Urol Oncol2017-06-01T00:00:002017Optimizing management of upper tract urothelial carcinoma.28867144Shah AY, Tannir NMUrologyEditorial Comment. Urology. 2017 11; 109:132.Urology2017-09-01T00:00:002017Editorial Comment.28877627Shah AY, Gao J, Siefker-Radtke AOImmunotherapyFive new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017 09; 9(10):781-784.Immunotherapy2017-09-01T00:00:002017Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer.30380460Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NMEuropean journal of cancer (Oxford, England : 1990)Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer. 2018 11; 104:188-194.Eur J Cancer2018-10-28T00:00:002018Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.Urology28870517Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AYClinical genitourinary cancerPhase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer. 2017 Aug 10.Clin Genitourin Cancer2017-08-10T00:00:002017Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.Authorship 9465141Authorship 9465157Authorship 9465202Authorship 9465692Authorship 9465711Authorship 9465841Authorship 9465932Authorship 9469061Authorship 9469091Authorship 9469152Authorship 946916330731013Alhalabi O, Shah AY, Lemke EA, Gao JOncology (Williston Park, N.Y.)Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. Oncology (Williston Park). 2019 Jan 17; 33(1):11-8.Oncology (Williston Park)2019-01-17T00:00:002019Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer.31075726Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NMEuropean journal of cancer (Oxford, England : 1990)Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer. 2019 06; 114:67-75.Eur J Cancer2019-05-07T00:00:002019Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.30719393Lemke EA, Shah AYJournal of the advanced practitioner in oncologyManagement of Advanced Bladder Cancer: An Update. J Adv Pract Oncol. 2018 May-Jun; 9(4):410-416.J Adv Pract Oncol2018-05-01T00:00:002018Management of Advanced Bladder Cancer: An Update.Authorship 955055231492380Yeboa DN, Shah AYInternational journal of radiation oncology, biology, physicsManaging Perplexing Intracranial Lesions. Int J Radiat Oncol Biol Phys. 2019 10 01; 105(2):244.Int J Radiat Oncol Biol Phys2019-10-01T00:00:002019Managing Perplexing Intracranial Lesions.Authorship 961939231786162Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYCEuropean urology oncologyOutcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. Eur Urol Oncol. 2021 02; 4(1):102-111.Eur Urol Oncol2019-11-28T00:00:002019Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.Authorship 979104832162795Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NMThe oncologistNivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist. 2020 03; 25(3):252-258.Oncologist2019-09-09T00:00:002019Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis.Authorship 987556432301013Alhalabi O, Rafei H, Bilen MA, Shah AYAdvances in experimental medicine and biologyCurrent Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol. 2020; 1244:107-147.Adv Exp Med Biol2020-01-01T00:00:002020Current Landscape of Immunotherapy in Genitourinary Malignancies.Authorship 10027141133046869Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma PNature medicineNeoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.Nat Med2020-10-12T00:00:002020Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.Authorship 100502411Authorship 10053701133216356McGregor BA, Campbell MT, Xie W, Farah S, Bilen MA, Schmidt AL, Sonpavde GP, Kilbridge KL, Choudhury AD, Mortazavi A, Shah AY, Venkatesan AM, Bubley GJ, Siefker-Radtke AO, McKay RR, Choueiri TKCancerResults of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. Cancer. 2021 03 15; 127(6):840-849.Cancer2020-11-20T00:00:002020Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.33187886Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NMUrologic oncologyOutcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol. 2021 02; 39(2):134.e9-134.e16.Urol Oncol2020-11-10T00:00:002020Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.Authorship 100693717Authorship 1007035233323389Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah VMolecular cancer research : MCRMolecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402.Mol Cancer Res2020-12-15T00:00:002020Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes.33329398Economides MP, Shah AY, Jimenez C, Habra MA, Desai M, Campbell MTFrontiers in endocrinologyA Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front Endocrinol (Lausanne). 2020; 11:594264.Front Endocrinol (Lausanne)2020-11-27T00:00:002020A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature.Authorship 1007390233343982Lemke EA, Shah AY, Campbell M, Tannir NMJournal of the advanced practitioner in oncologyReal-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis. J Adv Pract Oncol. 2019 May-Jun; 10(4):333-339.J Adv Pract Oncol2019-03-01T00:00:002019Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis.Authorship 10126931133657295Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Ju?rez VM, Hsieh JJ, Basso U, Shah AY, Su?rez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Zolnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ, CheckMate 9ER InvestigatorsThe New England journal of medicineNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2021 03 04; 384(9):829-841.N Engl J Med2021-03-04T00:00:002021Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.33739450Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NMInternational journal of cancerOutcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021 07 15; 149(2):387-393.Int J Cancer2021-03-24T00:00:002021Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.Authorship 10142438Authorship 1014314533747934Viscuse PV, Marques-Piubelli ML, Heberton MM, Parra ER, Shah AY, Siefker-Radtke A, Gao J, Goswami S, Ivan D, Curry JL, Campbell MTFrontiers in oncologyCase Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction. Front Oncol. 2021; 11:621591.Front Oncol2021-03-04T00:00:002021Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction.Authorship 10150343Authorship 1015611833818541Andreev-Drakhlin AY, Egoryan G, Shah AY, Msaouel P, Alhalabi O, Gao JCurrent opinion in oncologyThe evolving treatment landscape of advanced urothelial carcinoma. Curr Opin Oncol. 2021 05 01; 33(3):221-230.Curr Opin Oncol2021-05-01T00:00:002021The evolving treatment landscape of advanced urothelial carcinoma.33792094Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NMThe oncologistLenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist. 2021 06; 26(6):476-482.Oncologist2021-04-21T00:00:002021Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.Authorship 1017665733946504Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel PCancersEfficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel). 2021 Apr 30; 13(9).Cancers (Basel)2021-04-30T00:00:002021Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma.Authorship 1021383234143969Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tenn?e ?K, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJThe Lancet. OncologyLenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958.Lancet Oncol2021-06-15T00:00:002021Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.Authorship 10245581034228889De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang CBJU internationalDefinitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU Int. 2022 05; 129(5):610-620.BJU Int2021-07-23T00:00:002021Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.Authorship 1028738934459906Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis CJAMA network openEvaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open. 2021 08 02; 4(8):e2122998.JAMA Netw Open2021-08-02T00:00:002021Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors.Authorship 1031261734625389Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel PClinical genitourinary cancerEfficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer. 2021 12; 19(6):e401-e408.Clin Genitourin Cancer2021-09-15T00:00:002021Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.Authorship 10334566Authorship 103373114Authorship 1034300734737281Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma PNature communicationsPilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun. 2021 11 04; 12(1):6375.Nat Commun2021-11-04T00:00:002021Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma.34717797Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NMThe Lancet. OncologyDefinitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021 12; 22(12):1732-1739.Lancet Oncol2021-10-28T00:00:002021Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.34789422Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao JEuropean urology oncologyIntegrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol. 2023 04; 6(2):228-232.Eur Urol Oncol2021-11-14T00:00:002021Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer.Authorship 10351521434885132Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel PCancersAssociation of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel). 2021 Nov 30; 13(23).Cancers (Basel)2021-11-30T00:00:002021Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies.Authorship 1036366434972965Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MAAdvances in experimental medicine and biologyLandscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol. 2021; 1342:143-192.Adv Exp Med Biol2021-01-01T00:00:002021Landscape of Immunotherapy in Genitourinary Malignancies.Authorship 10380915Authorship 10391071235092681Daher M, Varghese J, Gruschkus SK, Jimenez C, Waguespack SG, Bedrose S, Altameemi L, Bazerbashi H, Naing A, Subaiah V, Campbell MT, Shah AY, Zhang M, Sheth RA, Karam JA, Wood CG, Perrier ND, Graham PH, Lee JE, Habra MAThe Journal of clinical endocrinology and metabolismTemporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. J Clin Endocrinol Metab. 2022 04 19; 107(5):1239-1246.J Clin Endocrinol Metab2022-04-19T00:00:002022Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience.35267435Moore JA, Slack RS, Lehner MJ, Campbell MT, Shah AY, Zhang M, Guo CC, Ward JF, Karam JA, Wood CG, Pisters LL, Tu SMCancersVery Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers (Basel). 2022 Feb 23; 14(5).Cancers (Basel)2022-02-23T00:00:002022Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications.Authorship 104337720Authorship 104381113Authorship 10442129Authorship 10445741735413951Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva RNature communicationsDistinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 04 12; 13(1):1970.Nat Commun2022-04-12T00:00:002022Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.35379845Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao JNature communicationsMTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun. 2022 04 04; 13(1):1797.Nat Commun2022-04-04T00:00:002022MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers.35442707Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NMScience translational medicineA phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med. 2022 04 20; 14(641):eabm6420.Sci Transl Med2022-04-20T00:00:002022A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.35475152Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AYBJUI compassMultimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass. 2022 Jan; 3(1):37-44.BJUI Compass2021-10-11T00:00:002021Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma.Authorship 1047418535688173Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Su?rez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TKThe Lancet. OncologyNivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022 07; 23(7):888-898.Lancet Oncol2022-06-07T00:00:002022Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.Authorship 10479631135691448Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang CInternational journal of radiation oncology, biology, physicsDefinitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):910-918.Int J Radiat Oncol Biol Phys2022-06-09T00:00:002022Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND.Authorship 10557466Authorship 10623237Authorship 1054708636569509Moore JA, Lehner MJ, Anfossi S, Datar S, Tidwell RS, Campbell M, Shah AY, Ward JF, Karam JA, Wood CG, Pisters LL, Calin GA, Tu SMBJUI compassPredictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries. BJUI Compass. 2023 Jan; 4(1):81-87.BJUI Compass2022-07-05T00:00:002022Predictive capacity of a miRNA panel in identifying teratoma in post-chemotherapy consolidation surgeries.36585982Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas AJournal of cancer research and clinical oncologyImplementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis. J Cancer Res Clin Oncol. 2023 Aug; 149(9):5841-5852.J Cancer Res Clin Oncol2022-12-31T00:00:002022Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis.35961847Labbate CV, Hensley PJ, Miest TS, Qiao W, Adibi M, Shah AY, Chery L, Papadopoulos J, Siefker-Radtke AO, Gao J, Guo CC, Czerniak BA, Navai N, Kamat AM, Dinney CP, Campbell MT, Matin SFUrologic oncologyLongitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Urol Oncol. 2022 10; 40(10):454.e17-454.e23.Urol Oncol2022-08-10T00:00:002022Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma.Authorship 10647891036863962Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel PEuropean urology focusCytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus. 2023 09; 9(5):734-741.Eur Urol Focus2023-02-28T00:00:002023Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.Authorship 10684521537072571Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah VNPJ precision oncologyPhase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37.NPJ Precis Oncol2023-04-18T00:00:002023Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.Authorship 1070246737164948Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CGNature communicationsPhase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun. 2023 05 10; 14(1):2684.Nat Commun2023-05-10T00:00:002023Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.Authorship 10722648Authorship 10733031137235818Singh AP, Xiao L, O'Brien BJ, Blondeau CE, Flowers CR, Bruera E, Morris VK, Shah AYJCO oncology practiceAssociation of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study. JCO Oncol Pract. 2024 Jan; 20(1):137-144.JCO Oncol Pract2023-05-26T00:00:002023Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study.37307533Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HAThe American journal of gastroenterologyImmune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. Am J Gastroenterol. 2023 09 01; 118(9):1609-1617.Am J Gastroenterol2023-06-13T00:00:002023Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors.Authorship 10809121237833193Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AOEuropean urology oncologyComparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol. 2023 12; 6(6):611-620.Eur Urol Oncol2023-10-11T00:00:002023Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.Authorship 10816221337858722Balderrama-Brondani V, Griffin AM, Owen TJ, Merriman KW, Chahla BB, Varghese J, Jimenez C, Waguespack SG, Graham PH, Perrier ND, Fisher SB, Karam JA, Shah AY, Campbell M, Hassan MM, Habra MAEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical EndocrinologistsIncidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry. Endocr Pract. 2024 Jan; 30(1):25-30.Endocr Pract2023-10-18T00:00:002023Incidence and Geographical Distribution of Adrenocortical Carcinoma: Retrospective Analysis of a State Cancer Registry.Authorship 1083768838035767Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel PThe oncologistTreatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. 2023 Nov 30.Oncologist2023-11-30T00:00:002023Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.Authorship 1086610938190801Fayle SE, Palaskas NL, Siddiqui BA, McQuade JL, Lin JS, Subudhi SK, Patel AB, Jenq RR, Shah AY, Spelman AR, Sun M, Marble BH, Wang YJournal of the National Comprehensive Cancer Network : JNCCNDevelopment of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events. J Natl Compr Canc Netw. 2024 Jan 08; 1-8.J Natl Compr Canc Netw2024-01-08T00:00:002024Development of a Strategic Initiative at MD Anderson Cancer Center to Improve Outcomes in Immune-Related Adverse Events.Authorship 1090613838478923Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NMThe oncologistEfficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist. 2024 Mar 13.Oncologist2024-03-13T00:00:002024Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma.true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professor